文献速递浆细胞疾病

治疗前代谢肿瘤体积和总病变糖酵解优于传统正电子发射断层扫描/计算机断层扫描变量在临床实践中对新诊断多发性骨髓瘤患者的结局预测

Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice.
PubMed 文献 · Br J Haematol · 2020-04-06

该回顾性研究在185例新诊断症状性多发性骨髓瘤患者中比较了代谢肿瘤体积(MTV)、总病变糖酵解(TLG)与高风险PET/CT变量对结局的预测价值,发现高负荷MTV(≥56.4 cm3)和高负荷TLG(≥166.4 g)独立预测更差的无进展生存和总生存,可能比高风险PET/CT变量更有用。

要点

  • 高负荷MTV(≥56.4 cm3)和高负荷TLG(≥166.4 g)与PFS和OS显著相关。
  • 高负荷MTV和TLG独立预测更差的PFS和OS。
  • 治疗前MTV和TLG可能比高风险PET/CT变量更有用。

核心结论

  • 治疗前MTV和TLG独立预测临床实践中的生存结局,可能比高风险PET/CT变量更有用。

研究设计与样本

  • 回顾性研究,纳入185例新诊断症状性多发性骨髓瘤患者。

主要发现

  • 高负荷MTV(≥56.4 cm3)、TLG(≥166.4 g)和高风险PET/CT表现在无进展生存和总生存上差异显著。
  • 高负荷MTV和TLG也预测年轻患者(年龄<75岁)和高危染色体异常患者的生存结局。
  • 高负荷MTV和TLG独立预测更差的无进展生存和总生存。

关键数值与推荐

  • 高风险PET/CT表现定义为至少存在以下一项:超过3个局灶性病变、最大标准化摄取值(SUVmax)>4.2和髓外疾病。
  • MTV定义为PET/CT上SUV≥2.5的可视化骨髓瘤病变体积。
  • TLG计算为所有病变的平均SUV与MTV乘积之和。
  • MTV和TLG的死亡预测最佳截断值分别为56.4 cm3和166.4 g。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are positron-emission tomography/computed tomography (PET/CT) variables for predicting multiple myeloma's (MM) outcome. We retrospectively investigated and compared the predictive value of MTV, TLG and high-risk PET/CT variables in clinical practice in 185 patients with newly diagnosed symptomatic MM. High-risk PET/CT findings were defined as the presence of at least one of the following: more than three focal lesions, maximum standardised uptake value (SUVmax ) >4·2 and extramedullary disease. MTV was defined as the volume of myeloma lesions visualised on PET/CT with SUV ≥ 2·5. TLG was calculated as the sum of the product of the average SUV and MTV of all lesions. The mortality prediction optimal cut-off values for MTV and TLG were 56·4 cm3 and 166·4 g, respectively. High-burden MTV (≥56·4 cm3 ), TLG (≥166·4 g) and high-risk PET/CT findings differed significantly in progression-free survival (PFS) and overall survival (OS). High-burden MTV and TLG findings also predicted survival outcomes in young patients (age <75 years) and patients with high-risk chromosomal abnormalities. High-burden MTV and TLG independently predicted both worse PFS and OS. Pre-treatment MTV and TLG independently predicted survival outcomes in clinical practice and may be more useful than high-risk PET/CT variables.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Terao T, Machida Y, Tsushima T, et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020. PMID: 32253760. doi:10.1111/bjh.16633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。